Mesenchymal Stem Cells Therapy for Treatment of Airway Remodeling in Mustard Patients
Pulmonary Disease
About this trial
This is an interventional treatment trial for Pulmonary Disease
Eligibility Criteria
Inclusion Criteria:
- patients who had a documentary exposure to mustard gas in the Iran-Iraq war
- their disease severity were as following based on spirometric: moderate 50<forced expiratory volume at one second (FEV1)<65 or severe 40<FEV1<50
- absence of contraindications spirometry (recent myocardial ischemia (MI)
- hemoptysis
- cerebral arterial aneurysm or aortic
- pulmonary embolism,
- uncontrolled blood pressure
- recent pneumothorax
- no doubt surgery/recent thoracic
- recent eye surgery, recent stroke
- non-availability in another research study at a same time
- no coagulation disorders
Exclusion Criteria:
- smoking
- the incidence of pneumonia during the study
- the incidence of transfusion reaction
- other medical condition (cardiovascular disease, hypertension, diabetes)
- visiting less than 2 times
Sites / Locations
Arms of the Study
Arm 1
Other
mesenchymal stem cell
There are complex sets of non-hematopoietic cells in bone marrow called mesenchymal progenitor cells (MPCs). MSCs are well-known as multipotent cells that have the ability to self-renew and differentiate into a great variety of cells. MSCs can be isolated from bone marrow, umbilical cord, peripheral blood and adipose tissue, and cultured in specific media. MSC colony formation, which is known as marrow-like stromal cells and MPCs, is similar to fibroblast colony forming unit (CFU-F) in in vitro condition. According to the International Society for Cellular Therapy (ISCT), MSCs can be easily detected or identified from other cells using flow cytometric analysis to detect specific surface markers